Adamed Group has just made an investment amount of US$50 million in Davipharm.
Davipharm manufactures a wide range of medicinal products for both Vietnamese and neighboring markets. “We consider our investment to be a launch pad for the further dynamic expansion of the Adamed Group into the Asia-Pacific region,” said Ph.D. Małgorzata Adamkiewicz, Director General of the Adamed Group.
“I am convinced that, in view of the scale of this transaction and further investments into the development of the company, our undertaking will constitute a milestone in strengthening economic relations between Poland and Vietnam”, Adamkiewicz added.
The deal provides for an extensive investment plan, including the transfer of Adamed’s knowledge and expertise.
In more than 10 years since its establishment, Davipharm has achieved a sizable share of the Vietnamese pharmaceutical market. “The investment by the Adamed Group is an opportunity for our continued dynamic development. Co-operation with such an experienced partner will enable us to reinforce our position in the local market and to expand in the Asia and Pacific region,” said Phạm Tai Truong, Director of Davipharm.
The investment in Vietnam forms part of the internationalization of the Adamed Group. In 2016, the company recorded a 15% increase in export revenues. The Adamed Group aims to constantly increase its foreign sales.
Davipharm – is a Vietnamese company established in 2004, which manufactures nearly 300 medicinal products in most therapeutic classes. It is the fastest-growing company in the Vietnamese pharmaceutical market. It exports its products to the Philippines, Cambodia and Myanmar.
Located in Binh Duong province near Ho Chi Minh City, it currently employs approximately 200 people.
